The complexity of the immune response to p53 loss is further highlighted by a recent study showing that loss of p53 in a prostate cancer model increases expression of CXCL17 and CXCL5 and consequent attraction of tumor-promoting Gr-1+CD11b+ cells (Bezzi et al., 2018). Here, CXCL5 is linked to prostate carcinoma.